[1]
|
Taurog, J.D., Chhabra, A. and Colbert, R.A. (2016) Ankylosing Spondylitis and Axial Spondyloarthritis. The New Eng-land Journal of Medicine, 374, 2563-2574. https://doi.org/10.1056/NEJMra1406182
|
[2]
|
Walker, J. (2006) An-kylosing Spondylitis. Nursing Standard, 20, 48-52. https://doi.org/10.7748/ns.20.46.48.s56
|
[3]
|
Golder, V. and Schachna, L. (2013) Ankylosing Spondylitis: An Update. Australian Family Physician, 42, 780-784.
|
[4]
|
Braun, J., Deodhar, A., Inman, R.D., van der Heijde, D., Mack, M., Xu, S. and Hsu, B. (2012) Golimumab Administered Subcu-taneously Every 4 Weeks in Ankylosing Spondylitis: 104-Week Results of the GO-RAISE Study. Annals of the Rheu-matic Diseases, 71, 661-667. https://doi.org/10.1136/ard.2011.154799
|
[5]
|
van der Heijde, D., Schiff, M.H., Sie-per, J., Kivitz, A.J., Wong, R.L., Kupper, H., Dijkmans, B.A., Mease, P.J. and Davis Jr., J.C. (2009) Adalimumab Effec-tiveness for the Treatment of Ankylosing Spondylitis Is Maintained for up to 2 Years: Long-Term Results from the ATLAS Trial. Annals of the Rheumatic Diseases, 68, 922-929.
https://doi.org/10.1136/ard.2007.087270
|
[6]
|
Vidal-Castiñeira, J.R., López-Vázquez, A., Diaz-Peña, R., Di-az-Bulnes, P., Martinez-Camblor, P., Coto, E., Coto-Segura, P., Bruges-Armas, J., Pinto, J.A., Blanco, F.J., et al. (2016) A Single Nucleotide Polymorphism in the Il17ra Promoter Is Associated with Functional Severity of Ankylosing Spon-dylitis. PLOS ONE, 11, e0158905.
https://doi.org/10.1371/journal.pone.0158905
|
[7]
|
Dubash, S., Bridgewood, C., McGonagle, D. and Marzo-Ortega, H. (2019) The Advent of IL-17A Blockade in Ankylosing Spondylitis: Secukinumab, Ixekizumab and Beyond. Expert Review of Clinical Immunology, 15, 123-134.
https://doi.org/10.1080/1744666X.2019.1561281
|
[8]
|
Pavelka, K., Kivitz, A., Dokoupilova, E., Blanco, R., Mara-diaga, M., Tahir, H., Pricop, L., Andersson, M., Readie, A. and Porter, B. (2017) Efficacy, Safety, and Tolerability of Secukinumab in Patients with Active Ankylosing Spondylitis: A Randomized, Double-Blind Phase 3 Study, MEASURE 3. Arthritis Research & Therapy, 19, Article No. 285.
https://doi.org/10.1186/s13075-017-1490-y
|
[9]
|
Huang, F., Sun, F., Wan, W., Wu, L., Dong, L., Zhang, X., Kim, T.H., Sengupta, R., Šenolt, L., Wang, Y., et al. (2019) Secukinumab Provides Rapid and Significant Improvement in the Signs and Symptoms of Ankylosing Spondylitis: Primary (16-Week) Results from a Phase 3 China-Centric Study, MEASURE 5. Annals of the Rheumatic Diseases, 78, 894-895. https://doi.org/10.1136/annrheumdis-2019-eular.2560
|
[10]
|
Marzo-Ortega, H., Sieper, J., Kivitz, A., Blanco, R., Cohen, M., Martin, R., Readie, A., Richards, H.B. and Porter, B. (2017) Secukinumab and Sustained Improvement in Signs and Symptoms of Patients with Active Ankylosing Spondylitis through Two Years: Results From a Phase III Study. Arthritis Care & Research, 69, 1020-1029.
https://doi.org/10.1002/acr.23233
|
[11]
|
Baraliakos, X., Braun, J., Deodhar, A., Poddubnyy, D., Kivitz, A., Tahir, H., Van den Bosch, F., Delicha, E.M., Talloczy, Z. and Fierlinger, A. (2019) Long-Term Efficacy and Safety of Secuki-numab 150 mg in Ankylosing Spondylitis: 5-Year Results from the Phase III MEASURE 1 Extension Study. RMD Open, 5, e001005.
https://doi.org/10.1136/rmdopen-2019-001005
|
[12]
|
Moreno-Ramos, M.J., Sanchez-Piedra, C., Martínez-González, O., Rodríguez-Lozano, C., Pérez-Garcia, C., Freire, M., Campos, C., Cáliz-Caliz, R., Calvo, J., Blanco-Madrigal, J.M., et al. (2022) Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry. Rheumatology and Therapy, 9, 1475-1476.
https://doi.org/10.1007/s40744-022-00479-0
|
[13]
|
Kiltz, U., Sfikakis, P.P., Gaffney, K., Sator, P.G., von Kie-drowski, R., Bounas, A., Gullick, N., Conrad, C., Rigopoulos, D., Lespessailles, E., et al. (2020) Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Eu-rope: Baseline Data from SERENA Study. Advances in Therapy, 37, 2865-2883. https://doi.org/10.1007/s12325-020-01352-8
|
[14]
|
Maksymowych, W.P., Strand, V., Nash, P., Yazici, Y., Thom, H., Hunger, M., Kalyvas, C., Gandhi, K.K., Porter, B. and Jugl, S.M. (2018) Comparative Effectiveness of Secukinumab and Adalimumab in Ankylosing Spondylitis as Assessed by Matching-Adjusted Indirect Comparison. European Journal of Rheumatology, 5, 216-223.
|
[15]
|
Ward, M.M., Deodhar, A., Gensler, L.S., Dubreuil, M., Yu, D., Khan, M.A., Ha-roon, N., Borenstein, D., Wang, R., Biehl, A., et al. (2019) 2019 Update of the American College of Rheumatolo-gy/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care & Research, 71, 1285-1299.
https://doi.org/10.1002/acr.24025
|
[16]
|
Huang, F., Sun, F., Wan, W.G., Wu, L.J., Dong, L.L., Zhang, X., Kim, T.H., Sengupta, R., Šenolt, L., Wang, Y., et al. (2020) Secukinumab Provided Significant and Sustained Improvement in the Signs and Symptoms of Ankylosing Spondylitis: Results from the 52-Week, Phase III China-Centric Study, MEASURE 5. Chinese Medical Journal, 133, 2521-2531. https://doi.org/10.1097/CM9.0000000000001099
|
[17]
|
Kivitz, A.J., Wagner, U., Dokoupilova, E., Supronik, J., Martin, R., Talloczy, Z., Richards, H.B. and Porter, B. (2018) Efficacy and Safety of Secukinumab 150 mg with and without Loading Regimen in Ankylosing Spondylitis: 104-Week Results from MEASURE 4 Study. Rheumatology and Therapy, 5, 447-462. https://doi.org/10.1007/s40744-018-0123-5
|
[18]
|
Pavelka, K., Kivitz, A.J., Dokoupilova, E., Blanco, R., Maradiaga, M., Tahir, H., Wang, Y., Porter, B.O., Stefanska, A., Richards, H.B., et al. (2020) Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study. ACR Open Rheumatology, 2, 119-127. https://doi.org/10.1002/acr2.11102
|
[19]
|
Marzo-Ortega, H., Sieper, J., Kivitz, A., Blanco, R., Cohen, M., Delicha, E.M., Rohrer, S. and Richards, H. (2017) Secukinumab Pro-vides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with High Retention Rate: 3-Year Results from the Phase III Trial, MEASURE 2. RMD Open, 3, e000592.
https://doi.org/10.1136/rmdopen-2017-000592
|
[20]
|
Braun, J., Baraliakos, X., Deodhar, A., Baeten, D., Sieper, J., Emery, P., Readie, A., Martin, R., Mpofu, S. and Richards, H.B. (2017) Effect of Secukinumab on Clinical and Radio-graphic Outcomes in Ankylosing Spondylitis: 2-Year Results from the Randomised Phase III MEASURE 1 Study. An-nals of the Rheumatic Diseases, 76, 1070-1077.
https://doi.org/10.1136/annrheumdis-2016-209730
|
[21]
|
Kishimoto, M., Taniguchi, A., Fujishige, A., Kaneko, S., Haemmerle, S., Porter, B.O. and Kobayashi, S. (2020) Efficacy and Safety of Secukinumab in Japanese Patients with Active Ankylosing Spondylitis: 24-Week Results from an Open-Label Phase 3 Study (MEASURE 2-J). Modern Rheu-matology, 30, 132-140.
https://doi.org/10.1080/14397595.2018.1538004
|
[22]
|
Zhou, Y., Ma, J., Ge, J., Wang, B., Yue, D. and Wang, W. (2020) Short-Term Efficacy and Safety of Secukinumab for Ankylosing Spondylitis: A Systematic Review and Me-ta-Analysis of RCTs. Mediators of Inflammation, 2020, Article ID: 1639016. https://doi.org/10.1155/2020/1639016
|
[23]
|
Deodhar, A.A., Dougados, M., Baeten, D.L., Wei, J.C.-C., Geusens, P., Readie, A., Richards, H.B., Martin, R. and Porter, B. (2016) Effect of Secukinumab on Patient-Reported Outcomes in Patients with Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1). Arthritis & Rheumatology, 68, 2901-2910.
https://doi.org/10.1002/art.39805
|
[24]
|
Gentileschi, S., Vitale, A., Rigante, D., Lopalco, G., Emmi, G., Orlando, I., Di Scala, G., Sota, J., Fabiani, C., Frediani, B., et al. (2018) Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers. The Israel Medical Associa-tion Journal: IMAJ, 20, 438-441.
|
[25]
|
Yamauchi, P.S., Bissonnette, R., Teixeira, H.D. and Valdecantos, W.C. (2016) Systematic Review of Efficacy of Anti-Tumor Necrosis Factor (TNF) Therapy in Patients with Psoriasis Previously Treated with a Different Anti-TNF Agent. Journal of the American Academy of Dermatology, 75, 612-618. https://doi.org/10.1016/j.jaad.2016.02.1221
|
[26]
|
Bombardieri, S., Ruiz, A.A., Fardellone, P., Geusens, P., McKenna, F., Unnebrink, K., Oezer, U., Kary, S., Kupper, H. and Burmester, G.R. (2007) Effectiveness of Adalimumab for Rheumatoid Arthritis in Patients with a History of TNF-Antagonist Therapy in Clinical Practice. Rheumatology, 46, 1191-1199.
https://doi.org/10.1093/rheumatology/kem091
|
[27]
|
Rudwaleit, M., Van den Bosch, F., Kron, M., Kary, S. and Kupper, H. (2010) Effectiveness and Safety of Adalimumab in Patients with Ankylosing Spondylitis or Psoriatic Arthri-tis and History of Anti-Tumor Necrosis Factor Therapy. Arthritis Research & Therapy, 12, Article No. R117. https://doi.org/10.1186/ar3054
|